Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib Journal Article


Authors: Morris, P. G.; Chen, C.; Steingart, R.; Fleisher, M.; Lin, N.; Moy, B.; Come, S.; Sugarman, S.; Abbruzzi, A.; Lehman, R.; Patil, S.; Dickler, M.; Mcarthur, H. L.; Winer, E.; Norton, L.; Hudis, C. A.; Dang, C.
Article Title: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
Abstract: Purpose: There are no validated methods of early detection of cardiotoxicity from trastuzumab (T) following anthracycline-based chemotherapy. Currently changes in left ventricular ejection fraction (LVEF) are assessed but this approach has limited sensitivity and specificity. Within a prospective feasibility study of dose-dense (dd) doxorubicin and cyclophosphamide (AC) → weekly paclitaxel (P) with T and lapatinib (L), we included a preplanned analysis of correlative cardiac Troponin I (cTnI) and C-reactive protein (CRP) as early biomarkers of cardiotoxicity. Experimental Design: As previously described, patients received ddACx 4→PTL→TL. LVEF was assessed at months 0, 2, 6, 9, and 18 and cTnI and CRP measured every 2 weeks during chemotherapy then at months 6, 9, and 18. These biomarkers were correlated with changes in LVEF. Results: Ninety-five patients enrolled. Overall, 3 (3%) patients withdrew during AC and 41 (43%) withdrew during PTL→TL, mostly due to diarrhea. Median LVEF was 68% (baseline), 69% (month 2), 65% (month 6), 65% (month 9), and 65% (month 18). The majority (67%) had a detectable cTnI during the study. The proportion of detectable cTnIs increased over time; 4% at baseline, 11% at month 2, and 50% at month 3. The timing of these detectable cTnIs preceded maximum-recorded decline in LVEF. However, overall, maximum cTnI levels did not correlate with LVEF declines. A detectable CRP was seen in 74/95 (78%) but did not correlate with LVEF declines. Conclusion: In patients receiving ddAC→PTL, cTnIs are commonly detected. These elevations may precede changes in LVEF but, as assessed in this trial, do not predict CHF. ©2011 AACR.
Journal Title: Clinical Cancer Research
Volume: 17
Issue: 10
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2011-05-15
Start Page: 3490
End Page: 3499
Language: English
DOI: 10.1158/1078-0432.ccr-10-1359
PROVIDER: scopus
PUBMED: 21372222
DOI/URL:
Notes: --- - "Export Date: 23 June 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Sujata Patil
    457 Patil
  2. Patrick Glyn Morris
    115 Morris
  3. Clifford Hudis
    892 Hudis
  4. Larry Norton
    671 Norton
  5. Chau Dang
    204 Dang
  6. Maura N Dickler
    256 Dickler
  7. Richard M Steingart
    132 Steingart
  8. Carol Chen
    31 Chen
  9. Martin Fleisher
    283 Fleisher
  10. Robert James Lehman
    10 Lehman